CHRS Coherus BioSciences
- 1.220
- -0.040-3.17%
- 1.290
- +0.070+5.74%
Coherus BioSciences News
Truist Financial Initiates Coherus BioSciences(CHRS.US) With Buy Rating
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Coherus Biosciences (CHRS) Receives a Buy From Barclays
Coherus BioSciences Is Maintained at Outperform by Baird
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Cuts Target Price to $4
TD Cowen Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Coherus Biosciences: Strong Financial Performance and Strategic Cost Management Drive Buy Rating
Coherus BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
JonesTrading Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $8
Coherus BioSciences Analyst Ratings
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12
Maintaining Buy Rating on Coherus Biosciences Amid Temporarily Disrupted Supply Chain
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Barclays Keeps Their Buy Rating on Coherus Biosciences (CHRS)
UBS Cuts Coherus to Neutral, Cites Limited Growth Opportunities
Analysis
Price Target
No Data
No Data